Adalimumab is a fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-α. Adalimumab is used for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

方法：ARPE 细胞与 MT2、TL-Om1 或 Jurkat 细胞共培养，用 Adalimumab (0.1-10 µg/mL) 处理 48 h，取上清液使用 CBA human inflammation cytokine kits 检测炎性细胞因子水平。
结果：IL-6、IL-10 和 IL-8 的产生水平不随 Adalimumab 的添加而改变。Adalimumab 以浓度依赖的方式降低肿瘤坏死因子 (TNF) 的分泌,Adalimumab ≥1.0 µg/mL 时未检测到 TNF。[1]
方法：CD4+T 细胞用 Adalimumab (1 µg/mL) 和 aCD3/CD28 mAb 处理 3 天，然后在存在 GolgiStop 的情况下刺激 PMA/离子霉素 3 h，使用质谱细胞术 (CyTOF) 检测 IL-10 表达。
结果：Adalimumab 治疗导致多种 CD4+T 细胞亚群中的 IL-10 诱导。[2]

方法：为研究对人类常染色体隐性遗传 RP 小鼠模型影响，将 Adalimumab (3 mg/kg) 腹腔注射给人常染色体隐性遗传性视网膜色素变性模型 rd10 小鼠，每三天一次，持续九天。
结果：Adalimumab 通过对 TUNEL 阳性细胞的数量进行评分来降低光感受器细胞的死亡。Adalimumab 还通过恢复总抗氧化能力和超氧化物歧化酶活性来改善抗氧化反应。Adalimumab 使 rd10 小鼠视网膜的能量和代谢模式正常化。[3]

Objective: Adalimumab induces apoptosis of THP-1 cells. Concentrations: 10μg/mL. Incubation Time: 6, 12, 18, 24, 30 hours. Method: THP-1 cells (0.5×106) were incubated with anti-FcRI mAb and anti-FcRII mAb, and then cultured with adalimumab, infliximab, huIgG or vehicle (PBS) alone as indicated. LPS (1μg/mL) was added in all culture conditions. Apoptosis was analyzed at different time points by staining with annexin V-FITC and propidium iodide, Apo2.7-PE-conjugated antibody, or 7AAD.

Objective: The distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. Formulation: PBS. Dosages: 2 mg/kg